Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Institute of Medical Genetics and Applied Genomics, |
RCV001291554 | SCV001480079 | likely pathogenic | not provided | 2021-02-01 | criteria provided, single submitter | clinical testing | |
Invitae | RCV003497920 | SCV004293705 | likely pathogenic | Cornelia de Lange syndrome 1 | 2023-09-17 | criteria provided, single submitter | clinical testing | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. Studies have shown that disruption of this splice site is associated with altered splicing resulting in unknown protein product impact (PMID: 24918291). ClinVar contains an entry for this variant (Variation ID: 996772). Disruption of this splice site has been observed in individuals with Cornelia de Lange syndrome (PMID: 24918291; Invitae). This variant is not present in population databases (gnomAD no frequency). This sequence change affects an acceptor splice site in intron 29 of the NIPBL gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in NIPBL are known to be pathogenic (PMID: 15318302, 19763162, 23505322, 29995837). |